Press release
Nonalcoholic Steatohepatitis (NASH) Market is Determined to Cross US$ 20.0 Billion By 2025
Nonalcoholic Steatohepatitis (NASH) Market
Nonalcoholic Steatohepatitis (NASH) Market 2018
Global Non-Alcoholic Steatohepatitis (NASH) market is expected to cross US$ 20.0 Billion by 2025 growing at a CAGR of more than 10.0% during given forecast period from 2016-2025.
The scope of the report includes a detailed study of global and regional markets for various types of Non alcoholic steatohepatitis with the reasons given for variations in the growth of the industry in certain regions. The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market.
The Nonalcoholic Steatohepatitis market is segmented on the lines of its Therapeutics such as GFT505, Obeticholic Acid (INT-747) Simtuzumab and Liraglutide (Victoza)Vitamin EPioglitazonePlacebo. The Nonalcoholic Steatohepatitis market geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
You Can Find Full Report: https://www.marketresearchengine.com/reportdetails/non-alcoholic-steatohepatitis-nash-market
Nonalcoholic Steatohepatitis market is segmented into therapeutic types and geography.
BY THERAPEUTICS
GFT505
Obeticholic Acid (INT-747)
Simtuzumab and Liraglutide (Victoza)
Pioglitazone
Placebo
Vitamin E
BY GEOGRAPHY
North America
Europe
Asia-Pacific
LAMEA
This report provides:
1) An overview of the global market for Non alcoholic Steatohepatitis and related technologies.
2) Analyses of global market trends and projections of compound annual growth rates (CAGRs) through 2025.
3) Identifications of new market opportunities and targeted promotional plans for Non alcoholic steatohepatitis market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
The major driving factors of Nonalcoholic Steatohepatitis (NASH) market are as follows:
1. There is a great increase in the cycles of the clinical trials with increased success rates. Hence there are increased chances of getting a commercial approval by 2017.
The restraining factors of Nonalcoholic Steatohepatitis (NASH) market are as follows:
1. The unexplained and complex physiological structure.
2. Inefficient diagnostics technology which lengthen the commercialization of NASH therapeutics.
Request Sample Report: https://www.marketresearchengine.com/reportdetails/non-alcoholic-steatohepatitis-nash-market
Table of Contents
1. INTRODUCTION
2. Assumptions and Research Methodology
3. Executive Summary: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market
4. Market Overview
5. Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecasts, By Marker Type
6. Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecasts, By End User
7. Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecasts, By Region
8. North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
9. Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
10. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
11. Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
12. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
13. Competition Landscape
13.1. Nonalcoholic Steatohepatitis (NASH) Biomarkers Market – Competition Matrix (By Tier and Size of companies) (2015)
13.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
13.2.1. BioPredictive S.A.S
13.2.2. One Way Liver S.L.
13.2.3. Genfit SA
13.2.4. Quest Diagnostics Incorporated
13.2.5. Prometheus Laboratories Inc. (Part of Nestle Health Sciences)
13.2.6. Siemens Healthcare Private Ltd. (now Siemens Healthineers)
13.2.7. Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIBE Diagnostics)
13.2.8. Exalenz Biosciences Ltd.
About Us
Market Research Engine (MRE) is a next-generation provider of syndicated research, customized research, and consulting services. MRE’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each Market Research Engine’s research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Media Contact
Company Name: Market Research Engine
Contact Person: John Bay
Email: john@marketresearchengine.com
Phone: +1-855-984-1862
Country: United States
Website: https://www.marketresearchengine.com/
Address: 3422 SW 15 Street, Suite #8942, Deerfield Beach, FL 33442, United States
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nonalcoholic Steatohepatitis (NASH) Market is Determined to Cross US$ 20.0 Billion By 2025 here
News-ID: 992545 • Views: …
More Releases from (MRE) Report
Weight Management Market is Expected To Be Worth US$ 442 Billion By 2025
New York, March 26, 2018:
Weight Management Market 2018
The Global Weight Management Market is expected to exceed more than US$ 442.0 Billion by 2025 at a CAGR of 8.0% in the given forecast period.
The scope of the report includes a detailed study of global and regional markets on Global Weight Management Market with the reasons given for variations in the growth of the industry in certain regions.
The report covers detailed…
Home Healthcare Market is Expected To Be Worth US$ 300 Billion By 2022
New York, March 26, 2018:
Home Healthcare Market 2018
The Global Home Healthcare Market is expected to exceed more than US$ 300.7 Billion by 2022 at a CAGR of 7.4% in the given forecast period.
The scope of the report includes a detailed study of global and regional markets on Global Home Healthcare Market with the reasons given for variations in the growth of the industry in certain regions.
The report covers detailed…
Healthcare 3D Printing Market is Forecast to Cross US$ 4 Billion By 2022
New York, March 26, 2018:
Healthcare 3D Printing Market 2018
The Global Healthcare 3D Printing Market is expected to exceed more than US$ 4 Billion by 2022 at a CAGR of 21.0% in the given forecast period.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include 3D Systems, Arcam AB, Renishaw PLC., EoS…
Tumor Ablation Market is Projected to Reach US$ 650 Million By 2022
New York, March 26, 2018:
Tumor Ablation Market 2018
The Global Tumor Ablation Market is expected to exceed more than US$ 650 Million by 2022 at a CAGR of 12.0% in the given forecast period.
The scope of the report includes a detailed study of global and regional markets for Global Tumor Ablation Market with the reasons given for variations in the growth of the industry in certain regions.
The report covers detailed…
More Releases for Steatohepatitis
Nonalcoholic Steatohepatitis Treatment Market Analysis
As per the research conducted by GME, the Global Nonalcoholic Steatohepatitis Treatment Market will grow with a CAGR value of 39.1% by 2026. Over the forecast era, the production of NASH biomarkers is expected to be aided by increasing demand for non-invasive diagnostic tools and increased patient awareness. The low use of invasive procedures for disease diagnosis is due to the high cost of liver biopsy, its invasiveness, and patients'…
Nonalcoholic Steatohepatitis Therapeutics Market: Trends, and Forecast 2025
According to a new market report published by Transparency Market Research “Nonalcoholic Steatohepatitis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2025”, the nonalcoholic steatohepatitis (NASH) therapeutics market is anticipated to expand at a CAGR of 10.7% from 2015 to 2025 to reach US$20.27 bn by 2025.
Nonalcoholic Steatohepatitis (NASH) is a syndrome that advances in patients who are not alcoholic; it causes liver damage…
Growing Trends in Nonalcoholic Steatohepatitis Therapeutics Market till 2025
The global nonalcoholic steatohepatitis therapeutics market is dominated by companies such as Intercept Pharmaceuticals Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Zydus Cadila, AstraZeneca plc., Gilead Sciences, Inc., and Immuron Ltd. Key companies are focusing on the introduction of new drugs and therapeutics to treat nonalcoholic steatohepatitis (NASH). As per the Natural Medical Journal, the occurrence of nonalcoholic fatty liver diseases is expected to increase in the U.S., which is likely…
Emerging Opportunities in Nonalcoholic Steatohepatitis Therapeutics Market
Global Nonalcoholic Steatohepatitis (NASH) Market: Snapshot
Nonalcoholic Steatohepatitis (NASH), a syndrome found in non-alcoholic patients, causes damage to liver that is histologically akin to alcoholic hepatitis. NASH results from fat in the liver, along with inflammation. Symptoms in NASH usually do not show, but it can be severe and lead to cirrhosis, which is permanent damage to the liver.
Those suffering from obesity, dyslipidemia, and glucose intolerance are most likely…
Global Non-alcoholic Steatohepatitis Market Research Report 2017
Report Hive Market Research Released a New Research Report of 114 pages on Title " Global Non-alcoholic Steatohepatitis Market Research Report 2017 "with detailed Analysis, Forecast and Strategies.
Non-alcoholic greasy liver malady (NAFLD) is one of the sorts of greasy liver which happens when fat is stored (steatosis) in the liver because of causes other than inordinate liquor utilize. NAFLD is the most widely recognized liver issue in created nations.
In this…
Global Nonalcoholic Steatohepatitis Therapeutics Market
Nonalcoholic Steatohepatitis (NASH), also called the ‘silent disease,’ is a kind of fatty liver disease which typically affects people that are obese or diabetic. This disease is more prevalent in the younger generation and causes liver inflammation and/or damage owing to the accumulation of fat within the liver. The exact cause of this disease is still not clear; however, research activities are underway for finding effective treatments to cure this…
